SG Americas Securities’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-15,074
| Closed | -$24K | – | 3439 |
|
|
2024
Q1 | $24K | Sell |
15,074
-8,652
| -36% | -$12.8K | ﹤0.01% | 2851 |
|
|
2023
Q4 | $20K | Buy |
23,726
+1,751
| +8% | +$1.54K | ﹤0.01% | 3008 |
|
|
2023
Q3 | $24K | Buy |
+21,975
| New | +$45.5K | ﹤0.01% | 3033 |
|
|
2023
Q2 | – | Sell |
-21,460
| Closed | -$88K | – | 3381 |
|
|
2023
Q1 | $88K | Buy |
21,460
+7,086
| +49% | +$32.8K | ﹤0.01% | 2953 |
|
|
2022
Q4 | $72K | Buy |
14,374
+3,732
| +35% | +$23.4K | ﹤0.01% | 2792 |
|
|
2022
Q3 | $139K | Sell |
10,642
-1,077
| -9% | -$16.3K | ﹤0.01% | 2606 |
|
|
2022
Q2 | $150K | Sell |
11,719
-46,441
| -80% | -$643K | ﹤0.01% | 2874 |
|
|
2022
Q1 | $887K | Sell |
58,160
-17,510
| -23% | -$273K | 0.01% | 1509 |
|
|
2021
Q4 | $1.34M | Buy |
75,670
+51,692
| +216% | +$992K | 0.01% | 1421 |
|
|
2021
Q3 | $504K | Sell |
23,978
-13,015
| -35% | -$287K | ﹤0.01% | 2503 |
|
|
2021
Q2 | $730K | Buy |
36,993
+32,677
| +757% | +$765K | ﹤0.01% | 1751 |
|
|
2021
Q1 | $125K | Sell |
4,316
-24,059
| -85% | -$674K | ﹤0.01% | 2965 |
|
|
2020
Q4 | $860K | Buy |
28,375
+16,675
| +143% | +$365K | ﹤0.01% | 1622 |
|
|
2020
Q3 | $186K | Sell |
11,700
-70,648
| -86% | -$1.29M | ﹤0.01% | 2189 |
|
|
2020
Q2 | $1.63M | Buy |
82,348
+71,842
| +684% | +$1.37M | 0.01% | 977 |
|
|
2020
Q1 | $130K | Buy |
10,506
+5,030
| +92% | +$82.1K | ﹤0.01% | 2803 |
|
|
2019
Q4 | $101K | Buy |
+5,476
| New | +$80.1K | ﹤0.01% | 2957 |
|
SG Americas Securities's NGM Position: Q2 2024 in Review
SG Americas Securities sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 15,074 shares — an estimated $24K sold.
SG Americas Securities first reported a position in NGM in Q4 2019 and held it in 17 quarters. The position peaked at $1.63M in Q2 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- SG Americas Securities reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- SG Americas Securities sold 15,074 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $24K.
- SG Americas Securities first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
- SG Americas Securities's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.63M in Q2 2020.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on SG Americas Securities's 13F filing for Q2 2024, filed 12 Jul 2024.